Am J Transplant, Volume 17, Suppl 3 Archives - Page 144 of 181 - ATC Abstracts

2017 American Transplant Congress
Kidney Size Does Not Matter: Should the Decision to Split Pediatric En Bloc Donor Kidneys Be Based on Donor Weight Rather Than Kidney Length?
A. Perry, J. Woloszyn, J. McVicar, J. Sageshima, R. Perez, C. Troppmann, C. Santhanakrishnan.
Division of Transplant Surgery, University of California, Davis, Sacramento, CA
Background: Deceased donor kidneys from pediatric donors have been used with good results. However, there is little consensus on the criteria used to safely split…
2017 American Transplant Congress
ABO Incompatible Deceased Donor Renal Transplantation: Exploring the Possibilities.
M. Sypek,^1,2 R. Masterson,^1,2 P. Hughes.^1,2
¹Dept of Nephrology, Royal Melbourne Hospital, Melbourne, Australia; ²University of Melbourne, Melbourne, Australia
Background: There is significant variation in waiting times for deceased donor (DD) renal transplants based on recipient blood group. Furthermore, there is an increased discard…
2017 American Transplant Congress
Increasing Living Donation by Implementing the Kidney Coach Program.
D. LaPointe Rudow, S. Geatrakas, J. Armenti, A. Tomback, R. Shapiro.
Recanati Miller Transplantation Institute, Mount Sinai Hospital, New York, NY
Introduction: It is firmly established that for patients requiring transplant, living donor kidney transplantation (LDKT) is better than deceased donor transplantation. However, recipients find it…
2017 American Transplant Congress
Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin.
J. Hazelcorn, R. Yau, N. Sabagha, M. Moaddab, M. Manson.
Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX
Purpose: Direct oral anticoagulants (DOAC) and calcineurin inhibitors (CNI) are both substrates of CYP 3A metabolism; therefore, the purpose of this study is to assess…
2017 American Transplant Congress
Sequential Surgical Strategy for Heart-Kidney Transplantation.
D. Mital,¹ M. Petruccione,¹ J. Brown,¹ S. Vasquez,¹ S. Wheaton,¹ W. Johnson,¹ C. Desai,¹ D. Chhabra,¹ G. Kinzler,¹ H. Sankary,¹ T. Lawrecki,^1,2 P. Pappas,² A. Tatooles,² M. Bresticker,² W. Cotts,² G. Bhat.²
¹Kidney Transplant Program, General Surgery, Advocate Christ Medical Center, Oak Lawn, IL; ²Heart Failure and Transplant Program, Advocate Christ Medical Center, Oak Lawn, IL
Purpose: To describe a unique sequential surgical strategy for heart-kidney transplantation.Methods: We reviewed all 6 patients who received combined heart-kidney transplants at our institution between…
2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
P. McMullen II,¹ J. Xin,¹ N. Brown,¹ R. Upchurch,¹ J. Weidner,¹ S. Fedson,² A. Husain,¹ S. Marino.¹
¹Pathology, University of Chicago Medicine, Chicago, IL; ²Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…
2017 American Transplant Congress
M1 Macrophage-Induced Loss of KLF15 Promotes Chronic Podocyte Injury.
S. Han,^1,2 Y. Kim,¹ S. Lee,¹ H. Lee,^1,2 R.-H. Cha,² J. Lee,^1,2 J. Lee,² D. Kim,^1,2 Y. Kim,^1,2 S. Yang.^1,2
¹Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ²Kidney Research Institute, Seoul National University, Seoul, Korea
Background: Krüppel-like factor 15 (KLF15), kidney-enriched transcription factor, is known to participate in the differentiation of podocyte. However, the implication of KLF15 in chronic podocyte…
2017 American Transplant Congress
Renal Transplant Recipients with Indication for Antiplatelet Therapy: Increased Risk for the Allograft?
T. Benko, M. Gottmann, S. Radunz, J. Treckmann, F. Saner, A. Paul, D. Hoyer.
General Visceral and Transplantation Surgery, University Hospital, Essen, Germany
Background Antiplatelet therapy is common in patients on the waiting list for kidney transplantation increasing the risk for perioperative blood loss. This study evaluates the…
2017 American Transplant Congress
Is There a [bdquo]Weekend Effect“ in Kidney Transplantation? – A Single Center Study.
K. Schütte-Nütgen, G. Thölking, H. Pavenstädt, B. Suwelack, S. Reuter.
Department of Internal Medicine D, University Hospital Münster, Münster, Germany
The "weekend effect" describes increased adverse events and outcomes for patients hospitalized on weekends due to limited resources at hospitals and - in the context…
2017 American Transplant Congress
Endovascular Management of Transplant Renal Artery Stenosis: A Safe and Effective Treatment.
A. Cavalcanti,¹ M. Durao,^1,2 B. Santos,^1,2 E. Tonato,^1,2 M. Doher,² N. Guimaraes-Souza,^1,2 L. Moreira Valle,¹ B. Affonso,¹ F. Nasser,¹ A. Pacheco-Silva.^1,2
¹Nephrology, Hospital Israelita Albert Einstein, São Paulo, Brazil; ²Nephrology, Universidade Federal de São Paulo, São Paulo, Brazil
Background:Transplant Renal Artery Stenosis (TRAS) is a low incidence complication, but if untreated, can lead to graft failure, refractory hypertension (HT) and reduced life expectancy.…